

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and a Waiver under 18 U.S.C. §208(b)(3)**

**Sandra Olson, M.D.**

**Committee:** The Peripheral and Central Nervous System Drugs Advisory Committee

**Meeting Date:** September 6-7, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to agenda item concerning the Joint Meeting of the Dental Products Panel of the Medical Devices Advisory Committee of the Center for Devices and Radiological Health and the Peripheral and Central Nervous System Drugs Advisory Committee of the Center for Drug Evaluation and Research to review and discuss peer-reviewed scientific literature on dental amalgam devices and its potential mercury toxicity, specifically as it relates to neurotoxic effects, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Stock	Competing Firm	Value between \$25,001 to \$50,000.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interest, the waiver is not valid.

\_\_\_\_\_  
/s/  
Signature of SGE

\_\_\_\_\_  
7/13/06  
Date